title: Phase II study of mitonafide in non-small cell lung cancer (NSCLC).
abstract: BACKGROUND
  The new intercalative agent Mitonafide was shown in early clinical trials to be toxic to the central nervous system when administered as a short intravenous infusion, but not when given as a 120-hour continuous infusion. Thus, clinical development in different tumor types was pursued using only this administration schedule.
  
  
  METHODS
  Forty-nine patients with previously untreated non-small cell lung cancer (NSCLC) and at least one measurable site received Mitonafide as a 120-hour continuous (5 days) infusion every 3 weeks. The starting dose was 170 mg/m2/day x 5 in the first 26 patients and 200 mg/m2/day x 5 in the remainder. Patients were evaluated for toxicity after each course and for response every two courses and remained on treatment until excessive toxicity or disease progression were observed. A special test, the "Mini-mental state", was used to assess patients' cognitive functions.
  
  
  RESULTS
  Of the 49 patients entered, 42 were evaluable for response and toxicity. Toxicity consisted mainly of myelosuppression and no neurologic side effects were observed. Only one patient presented a partial response.
  
  
  CONCLUSIONS
  Although definitively safe with this schedule of administration, Mitonafide is not active in NSCLC.
authors.affiliation: Hospital Universitario San Carlos, Madrid, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Casado
authors.forename: R
authors.initials: R
authors.lastname: Rosell
authors.forename: R
authors.initials: R
authors.lastname: García-Gómez
authors.forename: E
authors.initials: E
authors.lastname: Díaz-Rubio
authors.forename: G
authors.initials: G
authors.lastname: Pérez-Manga
authors.forename: A
authors.initials: A
authors.lastname: Font
authors.forename: A
authors.initials: A
authors.lastname: Benavides
authors.forename: M
authors.initials: M
authors.lastname: Martín
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D003071:Cognition / Q000187:drug effects; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007094:Imides / Q000008:administration & dosage* / Q000009:adverse effects; D007262:Infusions, Intravenous; D007546:Isoquinolines / Q000008:administration & dosage* / Q000009:adverse effects; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D053644:Naphthalimides
chemical_list: D000970:Antineoplastic Agents; D007094:Imides; D007546:Isoquinolines; D053644:Naphthalimides; C019215:mitonafide